XM does not provide services to residents of the United States of America.
G
G

Gilead

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Nasdaq top and bottom performing stocks at about 02:45 p.m. EST

BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EST Nasdaq 100 .NDX Top Performers Percent Change Super Micro Computer Inc SMCI.OQ +12.2% Warner Bros Discovery Inc WBD.OQ +10.9% Take-Two Interactive Software Inc TTWO.OQ +7.3% Trade Desk Inc TTD.OQ +5.3% Gilead Sciences Inc GILD.OQ +5.0% Bottom Performers Percent Change MercadoLibre Inc MELI.OQ -16.2% GlobalFoundries Inc GFS.OQ -4.3% Charter Communications Inc CHTR.OQ -3.7% CSX Corp CSX.OQ -3.2% Moderna Inc MRNA.OQ -3.0% The Na
C
C
G
M
T
U
T

U.S. STOCKS BorgWarner, Digital Realty, Take-Two

BUZZ-U.S. STOCKS ON THE MOVE-BorgWarner, Digital Realty, Take-Two Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes added to their gains on Thursday in the run-up to the Federal Reserve's interest-rate decision, extending a sharp rally sparked by Donald Trump's stunning comeback as U.S.
G
H
J
M
M
N
D
T
U
U
B
L
V
A
B
C
M

U.S. STOCKS Ralph Lauren, CoreCivic, WK Kellogg

BUZZ-U.S. STOCKS ON THE MOVE-Ralph Lauren, CoreCivic, WK Kellogg Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes held on to their gains on Thursday in the run-up to the Federal Reserve's interest-rate decision, extending a sharp rally sparked by Donald Trump's stunning comeback as U.S.
G
H
J
K
M
D
U
U
B
M
V
A
C
M

Gilead up after third-quarter results beat, forecast raise

BUZZ-Gilead up after third-quarter results beat, forecast raise Updates ** Drugmaker Gilead's GILD.O shares up 5 .7 % at $9 6.73; highest since April 2016 ** Company's Q3 results beat Wall Street expectations on Wednesday as sales climbed 7%, leading the drugmaker to raise its forecast for FY earnings ** Q3 adj EPS of $2.02 and Q3 rev. of $7.5 bln beat analysts' ests., a ccording to data compiled by LSEG ** Com pany expects annual adj.
G

U.S. STOCKS Guardant Health, AppLovin, Sarepta

BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, AppLovin, Sarepta Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq were set to open higher in the run-up to an interest-rate decision from the Federal Reserve on Thursday, extending a sharp rally sparked by Donald Trump's stunning comeback as U.S.
G
H
J
M
U
U
B
V
A
C
M

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.